DrugPatentWatch Database Preview

Iloprost - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for iloprost and what is the scope of freedom to operate?

Iloprost is the generic ingredient in one branded drug marketed by Actelion Pharms Ltd and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for iloprost. One supplier is listed for this compound.

Summary for iloprost

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	4
Suppliers / Packagers:	1
Bulk Api Vendors:	60
Clinical Trials:	85
Patent Applications:	4,799
Formulation / Manufacturing:	see details
DailyMed Link:	iloprost at DailyMed

Recent Clinical Trials for iloprost

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Innovation Fund Denmark	Phase 2/Phase 3
Jakob Stensballe, MD, PhD	Phase 2/Phase 3
Independent Research Fund Denmark	Phase 2/Phase 3

See all iloprost clinical trials

Pharmacology for iloprost

Drug Class

Prostacycline

Medical Subject Heading (MeSH) Categories for iloprost

Platelet Aggregation Inhibitors

Vasodilator Agents

Synonyms for iloprost

(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)

(16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2

(1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane

(1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane

(5E)-5-((3aS,4R,5R,6aS)-5-Hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid

(5e)-5-[(3as,4r,5r,6as)-5-Hydroxy-4-[(1e,3s,4r)-3-Hydroxy-4-Methyloct-1-En-6-Yn-1-Yl]hexahydropentalen-2(1h)-Ylidene]pentanoic Acid

(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid

(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic Acid

(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid

(5E)-5-[(3aS,5R,6aS)-4-[(E,3S)-4-methyl-3-oxidanyl-oct-1-en-6-ynyl]-5-oxidanyl-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid

(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid

(E)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-ynyl)hexahydropentalen-2(1H)-ylidene)pentanoic acid

(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure

(Z)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid

[3H]-Iloprost

1212AH

16(R)-Iloprost

5-((3aS,5R,6aS,E)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid

5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid

5-[[(2E,3aS,4R,5R,6aS)-Octahydro-5-hydroxy-4-[(1E,3S,4R)-3-hydroxy-4-methyl-1-octene-6-ynyl]pentalene]-2-ylidene]pentanoic acid

6,9.alpha.-Methylene-11.alpha.,15S-dihydroxy-16-methyl-prosta-5E,13E-dien-18-yn-1-oic acid

73873-87-7

74843-13-3

78919-13-8

A839531

AC-6105

AC1NSK5T

AC1O5JP3

AC1Q1J28

AHG2128QW6

AKOS024456922

AKOS025402197

AN-10394

AN-36592

B6933

BAY Q6256

BAY-q-6256

BC682483

BCP05834

BDBM23954

BRD-A45664787-001-01-4

BRD-A45664787-001-02-2

C22H32O4

CAS-78919-13-8

CHEBI:63916

CHEMBL494

Ciloprost

CS-5586

CTK8G0274

D02721

DB01088

DSSTox_CID_21046

DSSTox_GSID_41046

DSSTox_RID_79616

DTXSID2041046

Endoprost

GTPL1895

HIFJCPQKFCZDDL-ACWOEMLNSA-N

HIFJCPQKFCZDDL-JYTNZNGZSA-N

HMS2090A19

HMS3650E08

HY-A0096

IL2

Ilomedin

Ilomedine

Iloprost (USAN/INN)

Iloprost [BAN:INN]

Iloprost [USAN:INN:BAN]

Iloprost R-isomer

Iloprost, >=98% (HPLC)

Iloprostum

Iloprostum [Latin]

J-502615

K395

KS-00001F60

LS-101845

MolPort-023-276-312

MolPort-039-138-876

NCGC00181784-01

PDSP2_001536

Pentanoic acid, 5-((3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-, (5E)-

Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-

Pentanoic acid,5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]-,(5E)-

RP17693

SCHEMBL13386495

SCHEMBL13386497

SCHEMBL4357

SCHEMBL532499

SCHEMBL6083382

SH-401

SR-01000946274

SR-01000946274-1

SR-05000001498

SR-05000001498-1

SR-05000001498-2

Tox21_113586

UNII-AHG2128QW6

UNII-JED5K35YGL component HIFJCPQKFCZDDL-GBSCXWAGSA-N

Ventavis

Ventavis (TN)

ZINC3784120

ZK 00036374

ZK 36374

ZK-00036374

ZK-36374

ZK-363775

US Patents and Regulatory Information for iloprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion Pharms Ltd	VENTAVIS	iloprost	SOLUTION;INHALATION	021779-001	Dec 29, 2004		DISCN	No	No
Actelion Pharms Ltd	VENTAVIS	iloprost	SOLUTION;INHALATION	021779-003	Aug 7, 2009		RX	Yes	Yes
Actelion Pharms Ltd	VENTAVIS	iloprost	SOLUTION;INHALATION	021779-002	Dec 8, 2005		RX	Yes	Yes